Spectrum Pharmaceuticals, Inc clinical trials

Acquired by Zydus Lifesciences Limited, Jun 16, 2026 · source ↗

The registry lists 60 studies whose lead sponsor is Spectrum Pharmaceuticals, Inc. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 30, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 60. List all 60 → · All Zydus Lifesciences Limited studies →

• A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapyRecruitingNCT04570423Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 MutationsSuspendedNCT05378763Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibTerminatedNCT03744715Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationTerminatedNCT03318939Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-CancerCompletedNCT04187898Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study of Poziotinib in Japanese Patients With NSCLCTerminatedNCT04402008Phase 1/2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced MalignanciesTerminatedNCT04172597Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast CancerCompletedNCT01724866Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Study of IGN002 for Refractory NHLWithdrawnNCT02847949Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study of Poziotinib in Participants With HER2-Positive Metastatic Breast CancerCompletedNCT02659514Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Phase 1, Dose-Escalation Study of IGN002 in NHL SubjectsTerminatedNCT02519270Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and CyclophosphamideCompletedNCT02953340Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)CompletedNCT02643420Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.TerminatedNCT00322218Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)TerminatedNCT00384111Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like TherapyTerminatedNCT01510184Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)TerminatedNCT00743184Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma PatientsTerminatedNCT01420679Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT00998946Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Belinostat in Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT00865969Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)TerminatedNCT02563561Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)TerminatedNCT01587144Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the ProstateCompletedNCT00427219Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)TerminatedNCT01741155Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary CancerTerminatedNCT01773785Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate CancerCompletedNCT01252693Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's LymphomaTerminatedNCT01549886Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)TerminatedNCT01662102Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Zevalin Post-marketing Surveillance in JapanCompletedNCT01448928

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)TerminatedNCT03224182Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALLTerminatedNCT01439347Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult ParticipantsCompletedNCT04981704Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung CancerCompletedNCT00004202Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's LymphomaCompletedNCT00052442Phase 1/2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Radiation Therapy With or Without RSR13 in Treating Patients With Brain MetastasesCompletedNCT00005887Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With PoziotinibTerminatedNCT03804515Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)CompletedNCT00461591Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic LeukemiaCompletedNCT00495079Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based TreatmentCompletedNCT00606502Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male SubjectsCompletedNCT04436562Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast CancerTerminatedNCT03429101Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid TumorsCompletedNCT00765973Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated RashCompletedNCT00656786Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) ChemotherapyCompletedNCT03135951Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Safety and Efficacy of Marqibo in Metastatic Malignant Uveal MelanomaCompletedNCT00506142Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)TerminatedNCT01469221Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)CompletedNCT00598806Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder CancerTerminatedNCT01410565Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological MalignanciesCompletedNCT01317927Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's DiseaseCompletedNCT00364676Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited